A review of camizestrant's upcoming ODAC meeting
Review of 10 key early and late stage trials, including Relay and Scorpion's mutant selective PI3Kα inhibitors
New developments in metastatic and early stage breast cancer from Berlin
Highlights and lowlights from Day 1 of ESMO25
Standing out from the crowd – 6 ADC trends to watch out for at ESMO
Highlights from Arcus Bio's investor R&D Day on oncology and I&I
A look at the Genmab acquisition of Merus
Most tumours have defects in the antigen presentation machinery – here's one way to fix it
Regardless of the rumourmill, there are some new ADC data to explore
When too many cooks spoil the targeted therapy broth
While all eyes are on chemo combos in EGFR mt NSCLC, a bispecific ADC may give them a run for their money
The promise of RNA therapeutics has captivated the biotech world for a while, yet few have seen major…
What's story – is an emerging niche dead on arrival or will success come from next gen agents?
Super power can sometimes come from unexpected sources
New insights on emerging protein degrader classes
The conversation at this year’s ASCO sessions in some of the less sought after cancers carried an…
Some small molecules packing a punch
Six of the best...
Who's got the firepower in the SERD/PROTAC battle?
The opening day of ASCO25 served up exactly the kind of surprises that make this conference essential…
An emerging subniche in the ADC space
Upping the ante in the PD(L)1xVEGF bispecific antibody niche
A look at which TCEs induce a balanced KA-Pow Effect
As the PD(L)1 x VEGF niche explodes, small differences in design could make an impact on performance
What if everything we thought we knew about ‘immune cold’ breast cancers is wrong? This was one of…
It's easy to be lured in the promise of new compounds coming though...
Trials and tribulations associated with IO agents in solid tumours
Finding pearls before swine
A first look at some of the early-stage pipeline agents at ASCO25
